Letters to the editor

Sympathetic ophthalmia associated with high frequency deafness

Editor,—Sympathetic ophthalmia with deafness has been reported rarely.1 2 We describe one such case and explore a hypothesis whereby genetic susceptibility may be associated with cross reactivity of antigens derived from common neural crest tissue.

Case report
A 72 year old woman who had previously undergone a left trabeculectomy had a fall in which she sustained a Colles fracture and a left total hyphaema. By 14 days the blood had cleared sufficiently to reveal that she had expelled the entire left iris into the trabeculectomy bleb, with extensive dispersion of uveal pigment into the subconjunctival space. She was also found to have dislocated the lens, and had sustained a choroidal detachment (confirmed by ultrasonography). A non-granulomatous anterior uveitis was noted in the left eye at this time. The initial visual acuity was light perception in the left eye and 6/12 in the right eye.

On the 25th day after the original injury, she experienced pain and blurring of vision in her right eye, with the simultaneous onset of bilateral deafness (with an initial high frequency hearing loss of 60 dB). She was found to have a brisk anterior uveitis, with a dense vitritis in this eye, through which rugose choroidal thickening could just be discerned. At this stage, the right visual acuity had declined to 6/24, and the left eye achieved hand movements.

A diagnosis of sympathetic ophthalmia was made. She received two infusions of intravenous methylprednisolone (1 g each) and oral prednisolone (20 mg daily) was started. Cyclosporin A was commenced, and the dose adjusted to achieve a trough level of 200 µg/l (despite a history of breast cancer in remission). In view of the severity of the injury to the left eye, a left pars plana lensectomy and vitrectomy were performed to assess the visual potential of this eye. The retina was found to be flat, and the macula healthy; therefore, enucleation was not performed. By 3 months she had regained a visual acuity of 6/6 in the sympathising eye, and 6/12 in the exciting eye (with a contact lens incorporating a pupil and an aphakic correction).

However, at 4 months post-injury, reduction of the prednisolone dose to 12.5 mg, and reduction of cyclosporin A to give a trough level of 70 µg/l, was followed by a flare of anterior uveitis in both the exciting and sympathising eyes. This responded to increased prednisolone (15 mg) and an increase in the dose of cyclosporin A to achieve a trough level of 140 µg/l. At this time the exciting eye began to display white choroidal lesions consistent with the appearance of Dalen Fuchs nodules (Fig 1). Prednisolone was gradually reduced to 12.5 mg without further complications and she ultimately achieved a visual acuity of 6/9 in both eyes. Despite treatment, her hearing loss gradually progressed to 90 dB; this has not recovered.

Comment
Sympathetic ophthalmia with features of Vogt-Koyanagi-Harada disease (VKH), was initially reported in the 19th century.1 More recently, Nirankari et al have reported one case of sympathetic ophthalmia with profound high frequency deafness which did not recover.2 Rao and Marak have performed a clinicopathological survey of 100 pathological specimens of eyes enucleated because of sympathetic ophthalmia. Four of these had VKH overlap features, of which two had hearing loss. The association of sympathetic ophthalmia and deafness is clearly rare, which raises the question of what such overlap cases can teach us about the pathogenesis of VKH. Woods3 attempted to explain why deafness could occur in VKH, hypothesising that pigment present in the auditory labyrinth and the eye could be common targets of autoimmune. The auditory labyrinth and the uvea are known to have a common embryological origin in the neural crest. Could a genetic predisposition facilitate the recognition of such shared antigens? Sugita et al4 have recently reported that cytotoxic T cells from three patients with VKH and one with sympathetic ophthalmia reacted against the MART 1 melanoma antigen (an antigen carried by skin and eye melanocytes), when presented in association with HLA-A2. Interestingly, two of their three VKH patients carried HLA-A2, HLA-B51, HLA-DR4, and a further VKH patient carried the HLA-A2, and HLA-DR4 antigens. Their sympathetic ophthalmia patient was also A2 positive, but was not positive for either HLA-B51 or HLA-DR4. Our patient was HLA typed and found to carry HLA-A2, HLA-B51, HLA-DR4.

HLA-A2 and HLA-DR4 are common and linked antigens, occurring together in approximately 33% of the population, but HLA-B51 is less common. From 357 random transplant organ donors HLA typed over 3 years, we calculated the frequency of HLA-A2, HLA-B51, HLA-DR4 in the regional population. These specificities were present together in only seven donors, giving a frequency of 1.3%. We propose that patients carrying HLA-A2, HLA-B51, and HLA-DR4 are at increased risk of damage arising in melanocytes of diverse tissues when one tissue is injured, whether in VKH or sympathetic ophthalmia.

Marie Comer Craig Taylor Simon Chen Keith Martin Kerry Jordan Paul Meyer Department of Ophthalmology, Clinic 3, Addenbrooke’s Hospital, Cambridge, UK

Correspondence to: M Comer Accepted for publication 19 September 2000


Similarities in the packaging of cyanoacrylate nail glue and ophthalmic preparations: an ongoing problem

Editor,—We would like to raise concern over an ongoing problem—namely, the similarity between the packaging used for fingernail extension glue (cyanoacrylate “superglue”) and topical ophthalmic preparations.

These concerns were raised as long as 16 years ago and yet no action or progress has since been instituted by the manufacturers of these containers. Both nail glue and ophthalmic preparations are almost identically packaged in 5–10 ml clear, round bodied, soft plastic dropper type bottles with a white non-locking twist cap which are often manufactured in the same factory. The caps are even interchangeable.

Discrimination between these products is therefore made unnecessarily difficult, particularly for patients who need to use regular topical medication—for example, glaucoma and contact lens wearers’ and patients who are partially sighted or blind.


www.bjophthalmol.com
Furthermore, once superglue has been installed into the eye, it undergoes instantaneous polymerisation, so that no therapeutic window of opportunity exists to irrigate the glue from the eye.

Ocular injuries reported following superglue administration have included corneal abrasions, punctate epithelial keratopathy, eyelash loss, skin excoriation, and conjunctivitis. There is also the initial fear of blindness generated by an instant tarsorrhaphy.

CASE REPORT
There have been multiple reports of the mistaken ocular use of nail adhesive in adults. We have recently treated two paediatric patients for accidental ocular administration of nail adhesive glue, in one case a direct result of confusion about the packaging. The youngest was a baby aged 3 months, who had been prescribed chloramphenicol 0.5% eye drops for conjunctivitis. The mother confused the antibiotic eye drops with the nail adhesive drops which were mistakenly installed into the left eye, causing a partial tarsorrhaphy, eyelash clumping, and a corneal abrasion.

The second case was of a 3 year old child whose brother was receiving antibiotic eye drops for conjunctivitis. The child imitated her mother’s actions by installing drops in her own eye but used nail adhesive instead. This led to misdirection of her eyelashes and a corneal abrasion.

Both children responded well to the mechanical removal of the glued lashes and chloramphenicol 1% ointment.

COMMENT
Sixteen years have now passed since this issue was first raised, and we feel that the manufacturers of nail glue products should be forced to address some remedial action, to ensure that these preparations are packaged differently from therapeutic preparations in the future.

At the very least, nail glue products should be fitted with child safety caps to prevent any further unnecessary anxiety and ocular trauma.

ANDREW D NEEDHAM
SAJID NATHA
STEPHEN KAYE
Department of Ophthalmalogy, St Paul’s Eye Unit, Royal Liverpool University Hospital, Link Rd, Prescot Street, Liverpool L7 8XP, UK
Correspondence to: Mr Andrew Needham
Accepted for publication 31 October 2000

Disconjugate vertical ocular movement in a patient with locked-in syndrome

EDITOR—Locked-in syndrome is a rare paralytic state in which voluntary movements are affected. This uncommon de-esthetic state results in quadriplegia, loss of gestural or vocal communication with a defect in horizontal eye movements. However, conscious and vertical eye movements are spared, which enable the patient to communicate by way of ocular movement, either conjugate upward or downward.

Here, we report an unusual case of locked-in syndrome presenting disconjugate vertical and torsional ocular movement, mimicking seek-seen nystagmus (SSN).

CASE REPORT
A 30 year old man was brought to the emergency room. He was unable to move his extremities and all verbal communication other was not possible because he could not speak. Increased deep tendon reflex with bilateral extensor toe signs were noted. He could open his eyes. Visual acuity was uncheckable. Visual field appeared to be normal by a threatening test. Pupil size was equal and light reflex was prompt. Funduscopic examination did not show any remarkable findings.

On command, he showed conjugate vertical eye movements but he could not make horizontal gaze. Instead, full conjugate horizontal leftward deviation was obtained with cold water irrigation in the left ear, but nystagmus to the opposite side was absent. Caloric stimulation on the right ear was not performed because eardrum perforation was suspected. Doll’s eye manoeuvre showed full range of horizontal eye movements except for the adduction of the left eye, presumably due to left internuclear ophthalmoplegia. Convergence for near target was not possible. When the patient was asked to look to the right side, the right eye moved upward with intorsion, and at the same time, left eye moved downward and extorsion. It appeared to be a half cycle of SSN. When the patient was asked to look to the left side, the reverse half cycle of SSN was observed—the left eye moved upward with intorsion whereas right eye moved downward with extorsion. Horizontal gaze was limited, although there seemed to be minimal movement. The eyes that moved upward didn’t cross above the midline (Fig 1A, B).

In addition to the above findings, intermittent irregular jerky eye movements were detected. These also consisted of elevation with intorsion of one eye and synchronous depression and extorsion of the other eye. They appeared in a clustered pattern containing four to five cycles of SSN, beating at 0.5 and 1 Hz. Whether this phenomenon was purely voluntary or involuntary was not confirmed. It had persisted for 1 month.

Brain MRI revealed an extensive infarct in the ventral pons (Fig.1C).

COMMENT
We report an unusual non-concomitant vertical and torsional eye movements with a large brainstem infarction that rendered him “locked-in”. The main finding was intermittent disconjugate vertical eye movement with rising and intorting on one side while falling and extorting on the opposite side. It appeared to be SSN but it has not been previously reported in locked-in syndrome. Unlike the previously reported SSN cases, the half cycle of SSN was also induced when the patient attempted to look to the side.

Studies on SSN have suggested that intranuclear nucleus of Cajal (INC) mediate this phenomenon. The INC, a centre of integration of vertical and torsional eye movements, has extensive rostral and caudal connections. It receives ipsilateral input from the frontal cortex through the zona incerta, and contralateral input from the deep cerebellar nuclei and pretectum. The INC itself sends outputs to the ocular motor nuclei, the ipsilateral medullary vestibular nucleus, and the contralateral INC. In animal experiments, stimulation near the INC or stimulation of semicircular canals produced a half cycle of SSN. The underlying mechanism for a half cycle of SSN in our patient is not known. Horizontal conjugate deviation by cold caloric stimulation or oculocephalic reflex did not produce SSN, suggesting a vestibular mechanism may not explain SSN in this patient. Instead, we suggest that supranuclear control for horizontal gaze inappropriately sends signals to the INC, but a disturbance of neural integration in the INC may be responsible for the development of SSN. 1,2


This article is supported by grant no 01-1999-085-0 from the Seoul National University Hospital Research Fund.

SEONG-HO PARK
Department of Neurology, Boramae City Hospital, Korea

DUK L NA
Samsung Medical Center, Korea

MANHO KIM
Seoul National University Hospital, Clinical Research Institute, Seoul, Korea

www.bjo.bmj.com
Conjunctival CD5+ MALT lymphoma

EDITOR,—Primary ocular non-Hodgkin's lymphoma (NHL) may be found in the conjunctiva, eyelids, and lacrimal glands, but the majority occur in the orbit.1 Most primary ocular NHL are of B cell origin, either of the follicular, diffuse, or mixed cell type.1

According to the Revised European American classification of lymphoid neoplasms (REAL classification) the most common ocular NHL arising from mucosa associated lymphoid tissue (MALT) and the marginal zone of lymph follicles, is included in the group of extranodal peripheral B cell lymphomas.1 Histopathological features of marginal zone lymphoma (MZL) of the MALT type consists of a diffuse and parafollicular growth pattern and the presence of lymphoepithelial lesions.2

The tumour cells express monotypic surface Ig (sIg) and sometimes cytoplasmic Ig (cIg) (usually IgM), moreover the pan B cell antigens CD19, CD20, CD22, and CD79a.3 Typically, they are negative for CD5, CD10, and CD23.

Characteristically, MZL of the MALT type affects older patients and may remain localised for years,4 while disseminated disease involving bone marrow and peripheral blood is rare.5 Localised tumours may be cured with local irradiation, whereas disseminated stages of the disease are not curable and transformation into a large cell NHL may occur.6

We report a case of conjunctival MZL of the MALT type with an unusual clinical appearance, an CD5+ immunophenotype, and a history of idiopathic non-specific anterior uveitis.

CASE REPORT
A 79 year old man was referred to our hospital with a 3 month history of right eye discomfort and an epibulbar mass below the upper eyelid. Ophthalmological examination of the right eye revealed a reddish palpable tumour, 1.5 cm in diameter, located in the upper conjunctiva (Fig 1C). The extracolical movements were normal. Cornea and anterior chamber appeared clear; however, cortical and nuclear opacities were noted in the crystalline lens. Posterior segment examinations showed areas of confluent drusen and retinal pigment epithelium atrophy, with a normal optic disc. The patient's left eye had suffered from a severe anterior uveitis 30 years earlier and some recurrences, resulting in subsequent phthisis bulbi. Slit lamp examination revealed a low flare without cells in the anterior chamber, an indication of persisting vascular damage, moreover posterior synechiae. Lens opacification and age related macular degeneration were similar to the right eye. Because of the age related macular degeneration and the cataract visual acuity was “only” 20/100.

For the right eye, the phthisic left eye counting fingers/1 metre. The intraocular pressure was normal for the right eye (17 mm Hg), but hypotonic for the left eye (7 mm Hg). Because the uveitis was not due to any systemic or ocular disorder (characterised by blood chemistry tests and anterior chamber tap) it has to be diagnosed as idiopathic non-specific uveitis.

Orbital magnetic resonance imaging (MRI) showed a supraorbital lesion that surrounded the right eyeball (Fig 1A and B). Computed tomography (CT) scans demonstrated an intact bone structure of the orbit and no abnormalities were seen in the remaining skull, body or abdomen. As extensive as possible the anterior, visible part of the epibulbar lesion was surgically resected (Fig 1C and D), formalin fixed and paraffin...
embedded sent to the pathology department of Justus-Liebig-University Giessen, Germany, for immunohistological studies (Fig 2). Immunohistochemistry was done on the routinely formalin-fixed, paraffin embedded biopsy specimen after microwave pretreatment and pH-adjusted tissue sections. In the absence of analysable epithelium or mucosal glands, lymphoepithelial lesions were not assessed. However, general expression of CD20 and CD39 revealed the B cell nature of themore frequent lymphocytic infiltrates, but it was interesting that CD5 expression in about 50% of tumour cells was positive (Fig 2D), while few intermingled reactive T lymphocytes were observed (Fig 2C). Hints for a plasma cell differentiation were not detected by VS38C and reactivity for CD10, CD23, and CD30 was negative.

General physical examination of the patient showed no abnormality. There were no lymphadenopathy or hepatosplenomegaly. Periperal blood smears as well as bone marrow aspiration biopsy showed no signs for a disseminating lymphoma. All haematological and biochemical parameters were within the normal range. The M:E ratio was slightly elevated thymidine kinase (8 U/l) and β2-microglobulin levels (2.9 µg/l) suggestive for intensified cell growth. In conclusion, the final diagnosis of a low malignant conjunctival MALT lymphoma was established and confirmed by the German reference centre (Prof M-L Hansmann, University of Frankfurt). The patient underwent radiotherapy (40 Gy) in the right orbit (fractionated to 2 × 2 Gy/week). After radiotherapy, the lesion decreased markedly. No recurrence of the orbital lesion or any systemic involvement was noted during the follow up period of 18 months.

COMMENT

The immunophenotypic profiles of low grade B cell NHL are complex and still under investigation. Especially the T cell antigen CD5 is used to subclassify this group of B cell lymphomas. Since CD5+B cells were found to exhibit an immunoregulatory function, whether CD5 expression is relevant to the prognosis of patients with MALT lymphoma is controver- sial.

The association of MALT lymphomas with diffuse systemic disease, especially Sjögren’s syndrome and Hashimoto’s thyroiditis is well known. 10,11 Until now, the pathogenetic link of this relation is not clear, but an influence of a long standing inflammation and a consequent immuno-inflammatory lymphocytic subset are discussed to promote the development of MALT lymphomas. 12 Perhaps there is also a (autoimmune) correlation of anterior uveitis (of the contralateral eye) and MALT lymphoma as demonstrated here, but this cannot be proved and is perhaps incidental. The differential diagnoses of our patient are MZLs, bearing the unusual CD5+ phenotype, chronic lymphocytic B cell leukemia (B-CLL), and mantle cell lymphoma (MCL).

The last were excluded because of different morphological and phenotypic features. 13 Furthermore, B-CLL and MCL are usually widespread at diagnosis showing diffuse lymphadenopathy, substantial lymphocytosis, and bone marrow involvement. Both diseases are usually less aggressive than MALT lymphomas and usually not curable. 13 Although there was an extended growth from the epibulbar conjunc- tiva towards the deep orbit, our patient showed a localized stage of the disease, an indolent clinical course, and a favourable response to radiotherapy. Thus, we demonstrated an exceptional case of a conjunctival MZL of the MALT type with unusual CD5+ phenotype.

We thank Drs Iris Fenic, Joachim Weinrich, Karsten Munstedt, and Christian Vorwerk for critical reading and discussion. Furthermore, we thank all colleagues from the Medical School Bad Hersfeld and the Institute of Pathology, University Giessen, who were involved in the diagnosis and treatment of our patient.

ALEXANDER H HEURING
Department of Ophthalmology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany and Department of Ophthalmology, Kreiskrankenhaus Bad Hersfeld, Bad Hersfeld, Germany

WERNER W HÜTZ
Department of Ophthalmology, Kreiskrankenhaus Bad Hersfeld, Bad Hersfeld, Germany

FOLKER E FRANK
Department of Pathology, Justus-Liebig University Giessen, Giessen, Germany

Correspondence to: Dr Alexander H. Heuring, Augenklinik der Otto-von-Guericke-Universität, Leipzigerstrasse 44, D-39120 Magdeburg, alexander.heuring@t-online.de

Accepted for publication 1 November 2000


Autosomal dominant microcephaly— lymphedema-chorioretinal dysplasia syndrome

EDITOR.—We describe a family with chorio- retinal dysplasia, microcephaly, mental retardation, and lymphedema.

The proband presented with a severe multi- ple congenital malformation syndrome affecting the brain, heart, and eyes. Ocular anomalies included microphthalmia and chorioretinopa- thy. Pedal lymphedema was obvious at birth. These features overlap with three previously distinguished conditions (microcephaly with chorioretinopathy (MIM 156590), microcephaly with microphthalmia and retinal folds (MIM180060), and microcephaly and lymphedema (MIM129290)), and this suggests that they can be the variable expression of a single entity. In all children with micro- cephalia, a history of pedal oedema and detailed eye examination are essential.

CASE REPORTS

The index patient, a male, was born as the second child, to unrelated parents. He was born at a gestational age of 37 weeks by elective caesarean section for unexplained intrau- terine growth retardation. He was severely microcephalic and had marked lymphedema of the dorsum of both feet. Facial features were peculiar with, in addition to the micro- cephalic, low set ears and retrorhaphia. There was a transverse palmar groove on the left side, a right sided hydrocele and cardiac examination revealed the presence of an atrial septal defect, a small ventricle septal defect, and a right aortic arch. Neurological examination revealed axial hypotonia and severe development delay. Axial T1 weighted MR image at 4 months showed microcephaly and microsclen cephalic. Asymmetry of the eyes was noted and the right eye had an abnormal leucomicotic appearance. Corneal diameters were 11.5 mm on the right and 9 mm on the left. There was an iris bombans on the cataractous right eye with pressure of 30 mm Hg. Ultrasound showed the characteristics of a persistent hyperplastic primary vitreous (PHPV). After a surgical procedure with irid- ectomy the pressure normalised. On fundus-copy of the left eye a dystrophic retina with punched out lesions was seen (Fig 1). The second patient is the 3 year old brother of the index patient. He was microcephalic and showed marked lymphoedema of both feet at birth. Development was moderately retarded. Ophthalmological examination revealed bilateral chorioretinal dysplasia with the punched out lesions being localised in the periphery and midperiphery. Optic discs had a waxy pale aspect, macular reflex was dull (Fig 2). A B scan performed under general anaesthesia, with contact lens electrodes showed a severely attenuated cone and rod response. The third patient is the 27 year old father of both patients. He was mildly mentally retarded. Physical examination revealed microcephaly and dilated veins on the dorsal side of his feet. On fundus-copy subtle atrophic pigment epithelial changes could be noted temporally from the optic disc on the right eye; on the left eye atrophic changes were prominent.
was performed and showed a normal rod and cone response.

In all three patients high resolution chromosomal analysis on a peripheral blood lymphocyte culture revealed a 46,XY normal male karyotype after G-banding.

**COMMENT**

In literature, three distinct conditions have been delineated—microcephaly with chorioretinopathy (MIM 156590) microcephaly with microphthalmia and retinal folds (MIM180060), and microcephaly and lymphoedema (MIM152950). The features in the present family overlap with these three disorders. This suggests that, in at least some instances, they can be the variable expression of a single genetic condition.

In the syndrome with microcephaly with chorioretinopathy variable expressivity and the presence of mental retardation as an associated feature have repeatedly been reported. Male to male transmission of microcephaly, chorioretinal dysplasia, and mental retardation has also been described. Microcephaly with microphthalmia and retinal folds (MIM180060) has been reported as an apparently separate condition. However, microcephaly and microphthalmia were also present in the youngest child in the present family, but not in his father and brother, suggesting that both conditions might belong to the same spectrum of a single genetic disorder. Microcephaly and lymphoedema (MIM152950) was first described by Leung in 1985 in five individuals in a four generation family. There was no mental retardation. Congenital lymphoedema has also been described in three other isolated cases of microcephaly-chorioretinopathy. In the present family, the microcephaly and lymphoedema of the feet in patients 1 and 2 was associated with mental retardation as well as chorioretinopathy. This suggests that the three disorders previously distinguished could be the variable expression of a single genetic condition.

Ophthalmological findings reported in the autosomal dominant syndrome of microcephaly-chorioretinal dysplasia syndrome (MIM156590) include chorioretinal dysplasia, myopic astigmatism, and retinal dystrophy. Chorioretinal dysplasia represents the most common ocular abnormality seen in all patients of this report. Microphthalmia as seen in the proband has been reported before. Closed angle glaucoma secondary to a persistent primary hyperplastic vitreous (PHPV) has not been described. The spectrum of eye anomalies seen in the three patients of a single family clearly indicate the wide variety that can be associated with a single genetic entity.

Feingold and Bartoshesky and Limwongse et al suggested before that the three entities might represent the variable expression of a single entity. The clinical variability in the expression of this syndrome is remarkable. The proband of the present family had a severe multiple malformation syndrome, with anomalies of the brain, heart, and eyes. The presence of marked lymphoedema of the feet suggested the diagnosis which was confirmed upon examination of his brother and father, who had milder manifestations with microcephaly and developmental delay. Interest ingly, the eye anomalies had not been diagnosed in either of them, and in addition the pedal oedema had disappeared. This suggests that all children with microcephaly, a careful eye examination is warranted.

Counselling in microcephaly is difficult, and in the absence of a specific aetiological diagnosis, an empirical recurrence risk of 15–20% is often cited. Chorioretinal dysplasia-microcephaly-mental retardation syndrome (CDMMS) with autosomal recessive inheritance was described by McKusick et al.

In a sporadic patient with microcephaly, chorioretinal dysplasia, and mental retardation the clinical distinction between an autosomal dominant and recessive inheritance is not possible. However, the association with pedal lymphoedema could indicate probable autosomal dominant inheritance, since this has not been described in the autosomal recessive families.

Koen Devriendt is a senior clinical investigator of the Fund for Scientific Research-Flanders (Belgium) (FWO).

This paper was presented at the EPOG meeting Cambridge in September 2000 by I Casteels.

**Uveitis associated with OKT3 therapy for renal transplant rejection**

**EDITOR,—OKT3 (Ortho Biotech, Inc, Raritan, NJ, USA) is a murine monoclonal antibody to the CD3 receptor of human T lymphocytes, used in treatment of acute cellular graft rejection. Adverse effects of OKT3 include flu-like symptoms, hypotension, pulmonary oedema, cardiac dysfunction, asptic meningitis, and visual complications. We describe uveitis following administration of OKT3.**

**CASE REPORT**

A 51 year old man with polycystic renal disease underwent renal transplant from an unrelated donor. He was treated with antilym phocyte globulin and steroid in the immediate postoperative period, and was discharged 7 days after surgery, with a nadir creatinine of 1.1, on cyclosporine 100 mg twice daily, prednisone 200 mg/day, amiodipine, nystatin, and emotanide. Creatinine rose to 1.9 on postoperative day 30, and renal biopsy demonstrated lymphocytic interstitial infiltration, tubulitis, and endothelialitis. The patient was diagnosed with uveitis. He was started on a course of oral prednisolone, which led to a dramatic decrease in creatinine. At this time, he was treated with OKT3 (Ortho Biotech, Inc, Raritan, NJ, USA) for renal rejection. Signs of uveitis included visual acuity of 6/9, and a posterior synechiae.

**A LEYS**

Department of Ophthalmology, St Rafael University Hospitals, Capucijnenvoer 33, B-3000, Leuven, Belgium

**K DEVRIENDT**

Department of Clinical Genetics, Gastrohuisberg University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium

Correspondence to: I Casteels, Department of Ophthalmology, Capucijnenvoer 33, B-3000 Leuven ingele.casteels@uz.kuleuven.ac.be

Accepted for publication 7 November 2000

with BANFF 2B rejection, and given intravenous methylprednisolone 500 mg on the first day, tapered over 5 days to prednisone 30 mg/day. Creatinine level rose to 2.4 on day 35, and OKT3 (5 mg/day, intravenous) was begun.

On the fifth day of OKT3 therapy, the patient complained of right eye discomfort and redness. Over 2 days, the discomfort worsened and visual acuity fell, to 6/24− on the right and 6/9 on the left. Marked conjunctival injection, keratic precipitates, iris vessel congestion, white cells in the anterior chamber, hypopyon, and trace anterior vitreous cells were present in the right eye.

Inflammation obscured fundus details, but abnormalities were not detected by B-mode ultrasonography. The left eye exhibited conjunctival injection without intraocular inflammation.

Anterior chamber paracentesis from the right eye revealed white blood cells and no organisms. Cultures of aqueous humour and conjunctival swab were negative. Topical prednisolone 1% every 2 hours and hyoscine (scopolamine) 0.25% twice daily were begun in the right eye. OKT3 and FK506 were discontinued. Three days later, acuity improved to 6/18, conjunctival injection decreased, and the hypopyon resolved. Prednisolone drops were tapered and, within 5 days, vision improved to 6/6 in both eyes, and ocular inflammation cleared. Over the next week, topical medica
tions were tapered, then discontinued, with out return of inflammation.

COMMENT

OKT3 is implicated as a cause of anterior uveitis in our patient because of onset of inflammation soon after initiating OKT3 therapy, accelerated resolution of inflammation following discontinuation of OKT3, and lack of identifiable infectious aetiologies. We did not further pursue a cause and effect relation through OKT3 rechallenge because renal status had improved. It is unclear whether OKT3 acted alone or in combination to induce uveitis. This type of synergistic drug interaction is reported for rifabutin induced uveitis. This type of synergistic drug interaction is relevant in our patient, since uveitis was present in the right eye and hypopyon in both eyes, and ocular inflammation cleared.

Maxillary sinus non-Hodgkin’s lymphoma with orbital and intraocular involvement in the acquired immunodeficiency syndrome

Editor—In spite of its rare occurrence there is a well established association between the acquired immune deficiency syndrome (AIDS) and lymphoma, which is confirmed by the present paper. Recent studies indicate that the AIDS virus is able to cause lymphomas in the absence of a detectable prior lymphoproliferative disorder.

CASE REPORT

A 28 year old man with AIDS presented with right proptosis and recurrent sinusitis. His CD4+ count was 3 cells ×10^6/l and viral load 1 343 145 copies. Skull and orbital computed tomograph (CT) scans demonstrated right maxillary sinus opacification, right proptosis, and an anterior superotemporal mass in the right orbit. Cerebral image was unremarkable.

The oculomotor examination disclosed right eye proptosis, ptosis, and a visible mass on the temporal area of superior right lid, restricting spontaneous lid opening (Fig 1). There was bilateral lid oedema but no mass could be found on the left side. Right eye movements were restricted. Pupillary reflexes were normal in both eyes, and visual acuity reached 6/12 right eye and 6/6 left eye. Fundus examination revealed a serous retinal detachment and an intraocular mass.

Since a lymphoma was highly suspected specific therapy was started, and 5 days after the first chemotherapy, a significant reduction in the size of the mass was noted. Examination of the right fundus disclosed a large temporal scar and surprisingly, the left choroidal lesion had completely disappeared.

One month after the first chemotherapy, a drastic regression of the right mass occurred, causing total optophthalmoplegia, paralytic mydriasis, and amniorrhea. An elevated lesion was found on the bulbar conjunctiva from which a tissue specimen was easily obtained. Left visual acuity had also decreased to 6/60. At this moment, an extensive yellowish temporal choroidal lesion was found in the right fundus. Left fundus examination disclosed a serous retinal detachment involving the superior retina along the supratemporal arcade. CT scan showed that the right orbital mass expanded towards the apex, with cavernous sinus involvement. It also detected a left retro-ocular mass associated with a posterior scleral thickening, as well as multiple cerebral lesions. The patient’s condition rapidly deteriorated and he died a few days later. Postmortem examination was not performed.

The specimen removed from the right bulbar conjunctiva revealed a large cell, poorly differentiated neoplasm. Neoplastic cells with plasmacytoid differentiation were found in a scattered distribution. Immunohistochemical studies were done using the indirect immunoperoxidase method with diaminobenzidine (DAB), and the antigen retrieval method using heat or protease. The following markers were used: CD3, CD20, CD30, Kappa, Lambda, HMB45, Protrína S-100. The tumour cells were used: CD3, CD20, CD30, Kappa, Lambda, HMB45, Protrína S-100. The tumour cells were used: CD3, CD20, CD30, Kappa, Lambda, HMB45, Protrína S-100.
COMMENT
Classically, the AIDS associated lymphomas are of the B cell type and involve the CNS and the abdominal cavity, as opposed to the preferential ganglion involvement seen in immune competent patients. Such cases usually develop at advanced disease stage. Primary maxillary sinus lymphoma is rare, as is secondary orbital involvement. Malignant paranasal sinus tumour secondarily involves the orbit in 45% of the cases, but lymphomas are uncommon. Primary and secondary orbital lymphomas are rare, and bilateral occurrence is very unlikely. Rare cases of intraocular primary lymphomas were also previously described. Our patient had bilateral involvement of the sinuses, orbit, and intraocular structures, which was confirmed by CT scan, and although we didn’t obtain a specimen from the choroidal lesions for histological confirmation, the disappearance of the left lesion and the scarring on the right fundus just after treatment supports lymphoma as the diagnosis for the intraocular lesion. The immunohistochemistry was CD20 (L26) positive, and negative for all the other markers (CD3, CD30, Lambda, Kappa, S-100 protein, HMB-45), confirming the B cell origin.

Non-Hodgkin’s lymphoma in HIV infected patients tends to be of high grade malignancy, being very aggressive most of the times, with a mean survival of around 8 months. Our patient died after 3 months in spite of initial good response to chemotherapy. Radiotherapy has demonstrated good results for treatment of both systemic disease and in cases of orbital and intraocular involvement. On the other hand, chemotherapy has been good for systemic disease but has not been successfully used for intraocular disease.

Interestingly, our patient had a significant improvement after chemotherapy, but that was shortly followed by an intense reactivation, which was probably due to the high grade of malignancy.

Isolated or associated paranasal sinus, orbital, and intraocular lymphomas are considered to be very rare tumours, and even though their incidence has decreased in the HAART era, clinicians should be aware of this potential manifestation of non-Hodgkin’s lymphoma.

ANDRÉ LL CURI
Department of Ophthalmology, Fluminense Federal University, Niterói, Brazil

TERESA C FERREIRA
Department of Infectious Diseases, Santa Martha Hospital, Niterói, Brazil

JOSE C SADDY
Department of Pathology, Fluminense Federal University, Niterói, Brazil

RICARDO SALGADO
Department of Ophthalmology, Santa Martha Hospital, Niterói, Brazil

CARLOS PAVESIO
Department of Medical Retina, Moorfields Eye Hospital, City Road EC1V 2PD, London, UK

Correspondence to: Carlos Pavesio, Medical Retina Department, Moorfields Eye Hospital, City Road EC1V 2PD, London, UK

Accepted for publication 1 November 2000


Pythium insidiosum keratitis confirmed by DNA sequence analysis

EDITOR,—Pythium insidiosum is an unusual but serious oculopathogen. Although the organism grows as a mycelium in tissue, it is not a member of the fungal kingdom and its identification can be a challenge for a routine laboratory. We report a case of Pythium keratitis in which the organism was confirmed by nucleic acid sequencing.

CASE REPORT
A 32 year old man was referred from Kuala Lumpur having suffered with intractable keratitis of the left eye for 4 weeks. He gave a history of diabetes, disposable contact lens wear, and swimming in the Kelang River. Routine microbiological investigations had been negative. At presentation to Flinders Medical Centre, he was on topical antibacterial, antifungal, and antiamoebic medication. He had a large, tender, red, and purulent conjunctival discharge which was unresponsive to topical therapy. He was systemically well and had no ophthalmologic complaints of note.

Colonies grew rapidly on the primary fungal medium (plain Sabouraud’s agar, 28°C). They were white with a yellowish tinge, unusually flat, and difficult to cut and separate from the agar. Few septae and no spores were seen. The isolate was sent to a reference laboratory under suspicion of being a zygomycete. However, no further taxonomic clues were induced by standard measures so a molecular approach was employed. The methods have been described. Initially, a 510 base segment of the 18S ribosomal RNA gene was amplified (universal primers NS1 and NS2) and sequenced (Model 373A DNA sequencer, Applied Biosystems Inc). A search of databases (GenBank, EMBL) revealed homology to oomycetes. The isolate was then incubated for 48 hours in water containing autoclaved grass. Motile zoospores were observed, indicative of *P. insidiosum*. Other characteristics consistent with this identification were colony morphology, optimal temperature of growth (35°C), hypodiam (4–6 mm), and a good response to chemotherapy but has not been commonly used for intraocular disease. On the other hand, chemotherapy has been good for systemic disease but has not been successfully used for intraocular disease. Our patient had bilateral involvement of the sinuses, orbit, and intraocular structures, which was confirmed by CT scan, and although we didn’t obtain a specimen from the choroidal lesions for histological confirmation, the disappearance of the left lesion and the scarring on the right fundus just after treatment supports lymphoma as the diagnosis for the intraocular lesion. The immunohistochemistry was CD20 (L26) positive, and negative for all the other markers (CD3, CD30, Lambda, Kappa, S-100 protein, HMB-45), confirming the B cell origin.

Pythium insidiosum keratitis confirmed by DNA sequence analysis

EDITOR,—*Pythium insidiosum* is an unusual but serious oculopathogen. Although the organism grows as a mycelium in tissue, it is not a member of the fungal kingdom and its identification can be a challenge for a routine laboratory. We report a case of *Pythium* keratitis in which the organism was confirmed by nucleic acid sequencing.

CASE REPORT
A 32 year old man was referred from Kuala Lumpur having suffered with intractable keratitis of the left eye for 4 weeks. He gave a history of diabetes, disposable contact lens wear, and swimming in the Kelang River. Routine microbiological investigations had been negative. At presentation to Flinders Medical Centre, he was on topical antibacterial, antifungal, and antiamoebic medication. He had a large, tender, red, and purulent conjunctival discharge which was unresponsive to topical therapy. He was systemically well and had no ophthalmologic complaints of note.

Colonies grew rapidly on the primary fungal medium (plain Sabouraud’s agar, 28°C). They were white with a yellowish tinge, unusually flat, and difficult to cut and separate from the agar. Few septae and no spores were seen. The isolate was sent to a reference laboratory under suspicion of being a zygomycete. However, no further taxonomic clues were induced by standard measures so a molecular approach was employed. The methods have been described. Initially, a 510 base segment of the 18S ribosomal RNA gene was amplified (universal primers NS1 and NS2) and sequenced (Model 373A DNA sequencer, Applied Biosystems Inc). A search of databases (GenBank, EMBL) revealed homology to oomycetes. The isolate was then incubated for 48 hours in water containing autoclaved grass. Motile zoospores were observed, indicative of *P. insidiosum*. Other characteristics consistent with this identification were colony morphology, optimal temperature of growth (35°C), hypodiam (4–6 mm), and a good response to chemotherapy.
intercalary swellings in viable hyphae, vesicles at the end of spore discharge tubes, and spores germinating by means of germ tubes.⁷

To confirm the identification, the internal transcribed spacer (ITS) region defined by primers TW81 and AB28 (incorporating ITS1, the 5.8S gene and ITS2) was amplified. The 900 base pair product was sequenced by a direct double stranded DNA cycle method using primers 1–6 as detailed⁸ except for the substitution of primer 3 with 3c (5’-GCGACTTTGGGTAGGACCATT). The sequences were checked between complementary strands and shown to be 99.0% homologous with *P. insidiosum* reference strain CBS777.84 using CLUSTAL V software⁹ (CA Lévesque, personal communication). In comparison, the sequence was ~95% homologous with other *Pythium* species and ~90% homologous with other genera of oomycetes (BLAST database, NIH, Bethesda, MD, USA).

**COMMENT**

*P. insidiosum* is an aquatic, filamentous organism that produces heterokont, biflagellate zoospores, placing it as an oomycete in the Chromista. The only other human pathogen in this kingdom is *Rhinosporidium seeberi*, the agent of rhinosporidiosis. Oomycetes have a diploid genome and a cell wall consisting of cellulose compounds and glycan, features which distinguish them from the fungal groups of the kingdom Fungi. The identification of an oomycete in our patient can explain the PAS result and the lack of response to antifungals, there being no chitin or ergosterol in the cell wall, respectively. In addition to our genetic approach to confirming the identification, serological tests have been developed in Bangkok¹⁰ and at the Centers for Disease Control, Atlanta.

Oomycetes play an important part in the decomposition and recycling of decaying matter. Some species are parasitic on crops and fish. In mammals, *P. insidiosum* causes a granulomatous disease (“swamp cancer”) in several species including horses and dogs. A number of cases of human pythiosis have been reported, mostly subcutaneous infections and arthritis in thalassaemic patients in farming communities of South East Asia.¹¹ With respect to the eye, *P. insidiosum* has been responsible for periocular infections in Australia¹² and the USA¹³ and corneal ulcers in Thailand,¹⁴ Haiti,¹⁴ and New Zealand.¹⁴ Some patients have had no other medical history. Contact lens wear, exposure to river water, and diabetes were possible predisposing factors in our patient.

No cases of *Pythium* keratitis have been cured medically. A boy with facial pythiosis was cured without surgery by a 1 year course of terbinafine and itraconazole.¹⁵ For the cornea, however, it would be difficult to imagine a successful outcome given the destructive nature of the organism, the slow response if any to most antimicrobial agents, the probable delay in identification, and the need to prevent further tissue invasion. Transplantation may be the best option.

The introduction of corticosteroids in the management of fungal keratitis and, presumably, *Pythium* infection, must be approached with great caution. We gave prednisolone in the hope of reducing inflammation in the grafted cornea without encouraging a recurrence of the disease. It was fortunate that, apparently, no infectious elements had been left in the eye.

**PAUL R BADENOCH**

**DOUGLAS J COSTER**

Department of Ophthalmology, Flinders University of South Australia and Flinders Medical Centre, Bedford Park, South Australia

**BRUCE L WETHERALL**

**HELEN T BRETTIG**

Department of Clinical Microbiology and Infectious Diseases, Flinders Medical Centre, Bedford Park, South Australia

Michael A Rozenbiltds

Department of Anatomical Pathology, Flinders Medical Centre, Bedford Park, South Australia

André Drentth

Gabrielle Wagels

CRC for Tropical Plant Pathology, University of Queensland, St. Lucia, Queensland

Correspondence to: Dr Paul Badenoch, Department of Ophthalmology, Flinders Medical Centre, South Australia 5042, Australia

Accepted for publication 23 October 2000


Pythium insidiosum keratitis confirmed by DNA sequence analysis

PAUL R BADENOCH, DOUGLAS J COSTER, BRUCE L WETHERALL, HELEN T BRETTIG, MICHAEL A ROZENBILDS, ANDRÉ DRENTH and GABRIELE WAGELS

Br J Ophthalmol 2001 85: 496
doi: 10.1136/bjo.85.4.496g

Updated information and services can be found at:
http://bjo.bmj.com/content/85/4/496.8

These include:

References
This article cites 9 articles, 1 of which you can access for free at:
http://bjo.bmj.com/content/85/4/496.8#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Errata
An erratum has been published regarding this article. Please see next page or:
/content/85/6/761.7.full.pdf

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/
MAILBOX

Refractive, keratometric, and topographic determination of astigmatic axis after penetrating keratoplasty

Editor,—We read with interest the article by Sarhan et al on the effect of disagreement between refractive, keratometric, and topographic determination of astigmatic axis on suture removal after penetrating keratoplasty. The authors make some fundamental errors in their use of vectors for the calculation of mean astigmatism and have failed to refer to the dependence of astigmatism on the overall refractive power. As clearly discussed by several authors,1-5 it is inappropriate to analyse astigmatism without analysing the overall change in refractive power. The authors state that the two groups (agreement and disagreement) were comparable before suture removal in the preoperative vector of astigmatism but do not present the mean presuture removal vector. The authors appear to calculate a mean of the scalar component of astigmatism. Vectors have both direction and magnitude and cannot be averaged in this way; doing so leads to erroneous and incorrect conclusions.

It is also of concern that no post-suture removal data or refractive data are presented. It is also of concern that no post-suture removal data or refractive data are presented. It is also of concern that no post-suture removal data or refractive data are presented.

The authors also calculate the change in astigmatism using a method6 that relies on obtaining a square root—although no mention is made of which root they have used.7 As with any vector removal data, in the calculation of the mean change in the vector of astigmatism the directional component of the vector (for example, the ordinate axis of Fig 1) is disregarded with a test on the scalar. There are several published methods for analysing astigmatism,8 9 which the authors appear to have overlooked. The authors need to determine to what extent the degree and direction of change in astigmatism was in the direction of the sutures removed8 and how this differed between the two groups. The presence of pseudophakia is also relevant, since there may be an influence from non-corneal astigmatism. A table including details of each subject’s refraction before and after suture removal would have been illuminating.

Changes in refraction, keratometry, and topography might occur even without suture removal as part of the natural evolution of the cornea after penetrating keratoplasty so a control group is required. For example, the two groups might not have been similarly stable over time; in particular, we need to know whether the astigmatism within each group had been changing at the same or different rates.

The management of post-keratoplasty astigmatism remains an important subject and further work is needed.

STEPHEN KAYE
MARK BATTERBURY
ANTHONY FISHER

Corneal and External Eye Disease Service, St Paul’s Eye Unit, Liverpool University Hospital, Prescot Street, Liverpool L7 8XP, UK


Reply

Editor,—Kaye and colleagues make some valid though theoretical comments regarding vector analysis in the evaluation of post-keratoplasty astigmatism. We did use a software program for vector analysis based on the Jaffe and Clayton7 method of analysis of the vectors. Several formulas5 6 have been adopted to determine surgically induced astigmatism by vector analysis and further modifications have been carried out.6 The fundamental advantage of the Jaffe formula is its inherent consistency between refractive and keratometric changes and its sound mathematical basis.1 The authors of the letter make the valid comment that natural changes in refraction, keratometry, and topography might occur as part of the natural evolution of the cornea after penetrating keratoplasty. This is correct but again a very theoretical consideration. In practice, in the presence of significant post-keratoplasty astigmatism, most corneal surgeons will not wait and hope for natural progression to obviate the error. Intervention in the form of suture removal is undertaken between 4–6 months post-graft in order to influence the existing astigmatism. Such intervention does indeed influence the astigmatism, usually favourably. Rate of change of astigmatism, in the first 6 months does not influence the decision to remove sutures. The simple observation reported in this paper9 was that, in patients who have undergone penetrating keratoplasty, the axis of astigmatism is altered by refraction, keratometry, and topography does not always coincide. This observation is undisputed. The simple message of the paper was that when these three measures do not coincide, removal of sutures as indicated by topography is performed (which is the standard practice) does not always give the desired result as when the three measures do coincide. In the absence of conformity of the three measures, other clues such as inspection of the sutures and presence of striae and stress lines should also be considered before deciding which suture to remove.

A R S SARHAN
H S DUA
M BEACH
Division of Ophthalmology and Visual Sciences, University of Nottingham, University Hospital, Queen’s Medical Centre, Nottingham NG7 2UH, UK

3 Cravy TV. Calculation of the change in corneal astigmatism following cataract extraction. Ophthalmic Surg 1979;10:38–49.

Trans scleral cyclophotocoagulation in glaucoma after penetrating keratoplasty

Editor,—I read the article by Schlot et al with interest. The aim of their study was to determine the safety and effectiveness of transscleral diode laser cyclophotocoagulation (TDLC) in post inflammatory eyes with refractory glaucoma. In addition, the authors have rightly pointed out that management of inflammatory glaucoma is still a dilemma as many of the antiglaucoma drugs are either contraindicated or ineffective in such eyes. Further, some surgical procedures may activate the inflammatory diseases. I congratulate Schlot et al for highlighting the efficacy of TDLC in inflammatory glaucoma. In this context I would like to share our experience in one group of such eyes, “post-PK glaucoma.”

Glaucoma following penetrating keratoplasty continues to be a serious problem because of the frequency of its occurrence, its recalcitrant nature, and the risk of further damaging an already compromised anterior segment. We found in our study of eight eyes with uncontrolled post-PK glaucoma (Table 1) that all the eight eyes responded to the therapy and the mean IOP was 17.5±1.06 at the end of 24 weeks post-T DLC where the preoperative average intraocular pressure was 32.5 (SD 3.66) mm Hg. All but one patient were off systemic antiglaucoma therapy at 6 months. However, all the patients were taking topical timolol maleate 0.5% twice daily. The graft clarity was improved by 1+ in four eyes and 2+ in one. In three eyes the IOP was worsened. Visual acuity was static in six eyes and improved in one. In one eye the visual acuity was reduced from 3/60 to counting fingers. On the basis of our reports by Schlot et al in 2000 and Spencer and Vernon in 1999, we believe that TDLC is an alternative to treat post-PK glaucoma.

However, considering the non-improvement of visual acuity, worsening of the graft clarity in 25% of eyes, and repeat therapy in 25% of eyes, our question remained unanswered about the real efficacy of the procedure. It is, therefore, essential to know from the authors of the efficacy of TDLC in post-PK glaucoma. Again I congratulate the authors for bringing up this important issue.1 2

ANITA PANDA
BPKIHS, Dharan, Nepal

Correspondence to: anita94@yahoo.com

Argon laser and trichiasis: a helpful tip

Editor,—Trichiasis is a posterior misdirection of eyelashes. Owing to constant corneal irritation it can give rise to discomfort, recurrent infection, corneal ulceration, and panus formation. Several modalities of treatment exist which include epilation, electrolysis, cryotherapy, and argon laser thermoablation.

Argon laser offers the advantage of being a relatively simple, virtually painless method of destroying the eyelash follicle. It is especially useful when there is a need to limit contiguous tissue inflammation and destruction—for example, ocular pemphigoid. Argon laser can be precisely applied to the follicle with or without topical anaesthesia. A beam size of 50 μm, for a duration of 0.1 second and energy levels of 400–500 mJ is normally used in our clinic.

Thermoablation depends on the absorption of argon laser by pigment. In our experience, patients with chronic trichiasis, who have undergone repeated removal of eyelashes with other available methods, have pale hypopigmented lashes which do not absorb sufficient laser energy. This makes it difficult and sometimes impossible to get a result in spite of increasing the energy levels. Recently, we have used a blue marker pen to mark the base of the offending eyelash with the result that argon laser is better absorbed by the blue pigment. Once there is initial uptake subsequent shots down the lash root can be easily completed.

In conclusion, we have found the simple and inexpensive technique of marking eyelash bases useful in increasing the efficacy of argon laser photoepilation.

JAYASHREE SAHNI
DAVID CLARK
Wilton Hospital, Rice Lane, Liverpool L9 1AE, UK
Correspondence to: Jayashree Sahni
jayashree586@hotmail.com

OKN in the classic direction. In this central peripheral interaction, we proposed an important role for spatial-selective attention. It would be very interesting to find a method to monitor direction of attention simultaneously with OKN.

LUC CREVITS
Department of Neurology, Neuro-Ophthalmology Unit, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, Belgium
Correspondence to: luc.crevits@rug.ac.be


Dr Mauriello has relied on his vast clinical experience to put together an authoritative treatise on the prevention and management of problems in eyelid and lacrimal surgery. Each chapter in the three large sections—esthetic eyelid and midface surgery, functional eyelid surgery, and lacrimal surgery—has contributions by one set of authors and is preceded by introductory comments from the editor. The authors describe in detail their approaches to the very specific complications associated with particular surgical interventions.

The uniqueness of the text lies in its layout, as Dr Mauriello has enlisted the assistance of colleagues in various subspecialties of ophthalmic surgery, plastic surgeons, ophthalmic plastic surgeons, and lacrimal surgeons. Each chapter in the three large sections—esthetic eyelid and midface surgery, functional eyelid surgery, and lacrimal surgery—has contributions by one set of authors and is preceded by introductory comments from the editor. The authors describe in detail their approaches to the very specific complications associated with particular surgical interventions.

The uniqueness of the text lies in its layout, as Dr Mauriello has enlisted the assistance of colleagues in various subspecialties of ophthalmic surgery, plastic surgeons, ophthalmic plastic surgeons, and lacrimal surgeons. Each chapter in the three large sections—esthetic eyelid and midface surgery, functional eyelid surgery, and lacrimal surgery—has contributions by one set of authors and is preceded by introductory comments from the editor. The authors describe in detail their approaches to the very specific complications associated with particular surgical interventions.

Although this text can be read and enjoyed by a wide audience of medical practitioners, it will be most appreciated by ophthalmologists, ophthalmic plastic surgeons, plastic surgeons, and others performing surgery in the pericocular region. The eyelid surgery sections are particularly timely and well outlined, covering all essential topics such as endoscopic forehead elevation, laser resurfacing, and congenital blepharoptosis surgery. A wide spectrum of lacrimal disorders from infancy to adulthood are also described, including the management of lacrimal sac tumours. Relevant histopathology, neuroimaging, and schematic diagrams serve to emphasise surgical or anatomical principles where necessary. The scope of the text may be more useful for residents in the early stages of their training, but it does provide some indication of the breadth of knowledge and surgical techniques that need to be mastered in order to optimise functional and aesthetic surgical results. The intraoperative photographs, with meticulous attention to detail, provide careful instruction as to how to carry out surgical techniques with maximum success yet minimal complications. For surgeons embarking on a career in ophthalmic plastic surgery, or for established surgeons interested in optimising surgical results, this text is a welcome addition to any collection.

DAN DEANGELIS


The Neuro-ophthalmology Review Manual is the 5th edition of a well established favourite. The intention, as with previous editions, is to provide a readable compendium of “no nonsense” neuro-ophthalmology for neurologists, neurosurgeons, and ophthalmologists. The first edition of the book was envisaged as a coaching manual for the US Board examinations, but subsequent editions have been expanded in the hope of providing, in addition, a practical guide to the management of patients in the clinic and on the wards.

Apart from the senior author (Lanning B Kline) there are six contributing authors. The text of 280 pages is divided into 20 chapters, two of which are on the pharmacology and performances of higher visual function are completely new. The other chapters cover the full range of neuro-ophthalmic subject matter, including the major problems of disorders of eye movement, visual fields, pupils, and the optic disc. There are also chapters on the trigeminal nerve, the facial nerve, eyelid disorders, headache, carotid artery disease, and hysteria and malingerering. The chapters are not formally referenced, but an extensive bibliography of books, chapters, and original articles. The information is in note format, with line diagrams and a few tables.

Generally speaking an enormous amount of information is condensed within each chapter, but is readily accessible because of the layout. Mostly the information is clinically useful, with an emphasis on lists of differential diagnoses and pointers towards the diagnosis of individual conditions. There is a heavy reliance on clinical diagnosis, with little detail on laboratory tests, imaging, etc, and virtually none on management. For this reason an occasional item of information is rather arcane, and seems to predate the modern imaging era.

Examination candidates will find the dogmatic approach in some chapters—for example, “The six syndromes of the sixth nerve” or “The five syndromes of the fourth nerve”—very helpful in evolving a rigorous examination technique for topical diagnosis, as well as a useful way of retaining a lot of information. On the other hand any practising ophthalmologist would find it useful to be reminded of the essentials of, for example, disorders of the facial nerve or of higher visual function who confronted with such a patient in the clinic.

All in all this is a mine of useful information. It is comprehensive and covers the vast majority of practical neuro-ophthalmic scenarios, which may confront the ophthalmologist. It can be recommended as a revision aid for the Part 3 membership exam. It would be a useful quick reference book for both the ophthalmic casualty and the neuro-ophthalmology clinic.

JON S ELSTON

®
www.bjophthalmol.com
NOTICES

National prevention of blindness programmes and Vision 2020
The latest issue of Community Eye Health (36) discusses national prevention of blindness programmes. For further information please contact Community Eye Health, International Centre for Eye Health, Institute of Ophthalmology, 11–43 Bath Street, London EC1V 9EL. (Tel: (+44) (0) 20-7608 6909/6910/6923; fax: (+44) (0) 7250 3207; email: eyeresource@ucl.ac.uk) Annual subscription £25. Free to workers in developing countries.

Second Sight
Second Sight, a UK based charity whose aims are to eliminate the backlog of cataract blind in India by the year 2020 and to establish strong links between Indian and British ophthalmologists, will be sending volunteer surgeons to India early in 2001. Details can be found at the charity website at www.secondsight.org.uk or by contacting Dr Lucy Mathen (lucymathen@yahoo.com).

2nd Interdisciplinary Symposium on the Treatment of Autoimmune Disorders 2001
The 2nd Interdisciplinary Symposium on the Treatment of Autoimmune Disorders 2001 will take place on 7–9 June 2001 at the University Hospital, University of Kiel, Kiel, Germany. Further details: Prof Dr Med Michael Sticherling, Department of Dermatology, University of Kiel, Schittenhelmstrasse 7, D-24105 Kiel, Germany (tel: +49-431 597 1512; fax: +49-431 597 1611; email: msticherling@dermatology.uni-kiel.de).

European Intensive Program of Disease and Imaging of the Fundus
The European Intensive Program of Disease and Imaging of the Fundus under the auspices of the European Program Socrates will be held 2–12 July 2001 at the Clinique Ophthalmologique Universitaire, 40 avenue de Verdun, 94010 Créteil, France. Further details: Béatrice Rousseau (tel: (33 1) 45 17 52 22; fax: (33 1) 45 17 52 66).

American Institute of Ultrasound in Medicine—Millennium Ultrasound Course Series
A course entitled “Obstetrical and Gynecological Ultrasound” will be held in New York City, NY, on 24–26 August 2001. Further details: Stacey Bessling, Public Relations Coordinator, AJUM, 14750 Switzerland Lane, Suite 100, Laurel, MD 20707-5906, USA (tel: 301-498-4100; email: sbessling@ajum.org).

14th World Congress of the International Society for Laser Surgery and Medicine
The 14th World Congress of the International Society for Laser Surgery and Medicine is to be held on the 27–30 August 2001 at Sri Ramachandra Medical College and University Hospital, Chennai, India. The American Society of Lasers in Medicine and Surgery has indicated that it will designate the 14th World Congress of ILSM as its society’s co-sponsoring meeting. A pre-conference course and separate sessions in ophthalmology will be held as a part of this international meeting. Further details: Dr B Krishna Rau, President, 14th World Congress of the International Society for Laser Surgery and Medicine, Department of Surgery, D2 Ward, Sri Ramachandra Medical College and Research Institute, Porur, Chennai - 600 116, India (tel: 91-44-4765856; 4768027-28, 8527776, 8594804; fax: 91-44-8594578, 4767008; email: krishnar@iasimd01.vsnl.net.in and website: www.medindia.net/ilslm2001).

31st Cambridge Ophthalmological Symposium
The 31st Cambridge Ophthalmological Symposium will be held 3–5 September 2001 at St John’s College Cambridge. The subject is Retinal Detachment. Further details: COS Secretariat, Cambridge Conferences, The Lawn, 33 Church Street, Great Shelford, Cambridge CB2 5EL, UK (tel: 01223 847464; fax: 01223 847465; email: b.ashworth@easynet.co.uk).

1st Asia Pacific Forum on Quality Improvement in Health Care
The 1st Asia Pacific Forum on Quality Improvement in Health Care will be held from 19–21 September 2001 in Sydney, Australia. Presented by the BMJ Publishing Group (London, UK) and Institute for Healthcare Improvement (Boston, USA), with the support of the Commonwealth Department of Health and Aged Care (Australia), Safety and Quality Council (Australia), NSW Health (Australia) and Ministry of Health (New Zealand). Further details: quality@bma.org.uk; fax: +61 (0) 7383 6869.

41st St Andrew’s Day Festival Symposium on Therapeutics
The 41st St Andrew’s Day Festival Symposium on Therapeutics will be held on 6–7 December 2001 at the Royal College of Physicians of Edinburgh. Further details: Ms Eileen Strawn, Symposium Co-ordinator (tel: 0131 225 7324; fax: 0131 220 4393; email: e.strawn@rcpe.ac.uk; website: www.rcpe.ac.uk).

4th International Conference on the Adjuvant Therapy of Malignant Melanoma
The 4th International Conference on the adjuvant therapy of malignant melanoma will be held at The Royal College of Physicians, London on 15–16 March 2002. Further details: Conference Secretariat, CCI Ltd, 2 Palmerston Court, Palmerston Way, London SW8 4AJ, UK (tel: + 44 (0) 20 7720 0600; fax: + 44 (0) 20 7720 7177; email: melanoma@confcomm.co.uk; website: www.confcomm.co.uk/Melanoma).

XXIXth International Congress of Ophthalmology
The XXIXth International Congress of Ophthalmology will be held on 21–25 April 2002 in Sydney, Australia. Further details: Congress Secretariat, CIC Australia Pty Ltd, Box 2609, Sydney, NSW 2001, Australia (tel: +61 2 9241 1478; fax: +61 2 9251 3552; email: ophthalm@icmsaustr.com.au; website: www.ophthalmology.aust.com).

International Society for Behçet’s Disease
The International Society for Behçet’s Disease was inaugurated at the 9th International Congress on Behçet’s Disease. Professor Shigeaki Ohno represents the ophthalmology division (Department of Ophthalmology and Visual Sciences, Hokkaido University Graduate School of Medicine, Sapporo, Japan: tel: +81-11-716-1161 (ext 5944); fax +81-11-736-0952; email: sohno@med.hokudai.ac.jp). The 10th International Congress on Behçet’s Disease will be held in Berlin 27–29 June 2002. Further details: Professor Ch Zouboulis (email: zoubbere@zedat.fu-berlin.de).

Correction
A mistake occurred in a letter to the editor by Badenoch et al published in the April issue of BJ O (2001;85:502–3). In the last sentence of the third paragraph under the heading “Case report” the hyphal diameter is given as 4–6 mm; this should be 4–6 μm.

www.bjophthalmol.com